Berlex also markets FLUDARA® (fludarabine phosphate) for injection for the treatment refractory chronic lymphocytic leukemia (CLL). CLL is the most prevalent form of adult leukemia, in the Western Hemisphere, affecting approximately 120,000 patients in the United States and Europe